Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice

Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice

Daily, systemic injections of a positive AMPA-type glutamate receptor modulator (ampakine) have been shown to reduce synaptic plasticity defects in rodent models of aging and early-stage Huntington's disease (HD). Here we report that long-term ampakine treatment markedly slows the progression o...

Full description

Bibliographic Details
Main Authors: Danielle A. Simmons, Rishi A. Mehta, Julie C. Lauterborn, Christine M. Gall, Gary Lynch
Format: Article
Language:English
Published: Elsevier 2011-02-01
Series:Neurobiology of Disease
Subjects:
Therapeutic
DARPP-32
Rotarod
Huntingtin
BDNF
Neurotrophin
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996110003499

Internet

http://www.sciencedirect.com/science/article/pii/S0969996110003499

Similar Items